IGC Pharma

Exciting news from IGC Pharma! We are pleased to announce the expansion of our #Phase2 #clinicaltrial for IGC-AD1 to Baycrest in Toronto, marking a key milestone in the fight against #Alzheimer's-related #agitation. Baycrest, a global leader in #brainhealth and aging, has enrolled its first #patients in this groundbreaking trial. With 13 additional sites across North America, we are committed to advancing innovative #treatments that could significantly improve the #qualityoflife for patients and their #caregivers. More info here: https://lnkd.in/eVDiwPgY   #AlzheimersResearch #IGCPharma #Baycrest #ClinicalTrials #BrainHealth #PatientCare #InnovationInHealth #Neurology #DementiaCare

#Alzheimer’s #research is reaching new heights, with billions invested and the #FDA recently approving two groundbreaking new drugs. At IGC Pharma, we’re honored to work alongside the late Dr. Lopera, Dr. Aguillon and the GNA - Grupo de Neurociencias de Antioquia, driving forward research to improve the quality of life for Alzheimer’s patients. This video is just a teaser, offering a glimpse into the #inspiring stories and advancements we’ve made. The full story will be revealed in our upcoming documentary, where we dive deeper into the groundbreaking work being done. Stay tuned—there’s so much more to come. Together, we’re bringing #hope to #patients and their families. #AlzheimersResearch #IGCPharma #Neuroscience #HopeForAlzheimers Ram Mukunda Claudia Grimaldi Evelyn Gutiérrez . Thanks! Gustavo Dallmeier

IGC Pharma Wins Two Awards for Alzheimer’s Research! We are thrilled to announce that IGC Pharma has received Third Prize and the Disproportionate Impact Prize in the #NIA's PREPARE Challenge! Our #AI-driven research is paving the way for #earlyprediction tools for Alzheimer’s, with the goal of detecting #cognitivedecline up to 20 years before symptoms appear. Learn more about the Phase 1 winners and top datasets used in the challenge here: https://lnkd.in/eERe624E A special congratulations to the dedicated team who made this achievement possible: Paola Ruiz Puentes, Daniel Andrés Crovo Pérez, Néstor González, Pablo Arbeláez (https://lnkd.in/eZMZmaMd), Maria Juanita Arbelaez Duarte, Maria Alejandra Tanagrife, and Evelyn Gutiérrez. Your hard work and commitment are making a difference! At IGC Pharma, we are committed to improving patient outcomes, reducing the caregiving burden, and creating lasting value for patients, #caregivers, and #healthcaresystems. #AlzheimersResearch #AI #HealthcareInnovation #IGCPharma #PREPAREChallenge

Episode 4: Compassionate Message: We at IGC Pharma are deeply grateful to everyone who has followed this powerful story. In the face of #Alzheimer's, love and compassion are our greatest strengths. Mariangela’s heartfelt message reminds us to cherish every moment with our loved ones. Your support and attention make a #world of difference as we continue to raise awareness and spread hope for those affected by this #disease. Together, we can make strides towards better care, understanding, and treatment. #AlzheimersAwareness #HopeForACure #IGCPharma

Episode 3: The Responsibility of the Industry "The search for treatments and solutions to #Alzheimer's requires dedication from everyone, especially within the #pharma industry. Mariangela shares her perspective on how families, like hers, look to companies such as IGC Pharma to lead the way in research and #innovation. Together, we hold the responsibility to push for progress and #hope." #igcpharma #AlzheimersAwareness #EndAlzheimers #WorldAlzheimersDay

Episode 2: Behind every #Alzheimer’s patient is a network of devoted #caregivers, shouldering the emotional and physical demands of the #disease. In this video, we hear firsthand the #challenges and strength required to care for a loved one with Alzheimer’s. This powerful continuation is a reminder of the importance of support—for both those diagnosed and the ones standing by their side.   #igcpharma #AlzheimersAwareness #EndAlzheimers #WorldAlzheimersDay

Facing Alzheimer’s: A Family’s Journey 💜 In honor of Alzheimer’s Day on September 21st, IGC Pharma wants to share the stories of those living with the #disease and the families caring for them. In this moving #testimony, a daughter opens up about the profound #challenges of caring for her mother with Alzheimer’s. Her #story is one of strength, love, and the daily struggles families face. Together, let’s raise awareness, share #hope, and work toward a brighter future.   #igcpharma #AlzheimersAwareness #EndAlzheimers #WorldAlzheimersDay

IGC Pharma announces new data supporting IGC-AD1 as a promising treatment for #Alzheimer's. The #preclinical #research highlights IGC-AD1's positive effects on tau tangles and improvements in spatial #memory. By targeting both #amyloid #plaques and tau #pathology, IGC-AD1 is uniquely positioned in the Alzheimer's field as a potential disease-modifying drug and a therapy for specific #symptoms, such as #agitation in Alzheimer's patients. Learn more at https://lnkd.in/ef72pZ2K   #IGCPharma #IGCAD1 #Spatialmemory #Preclinicaldata #DrugDevelopment #Alzheimers #Healthcare #Biotech #Tau

World Alzheimer's Month: Focusing on #LatinAmerica As we recognize World #AlzheimersMonth, it's essential to highlight the growing challenge that #Alzheimer's and #dementia pose in Latin America. With an estimated 19.38 million people in the region expected to be living with dementia by 2050, it’s crucial to increase #awareness and improve access to #diagnosis and #care. In this carousel, IGC Pharma explores #keyfactors: • High rates of #undiagnosed dementia due to #stigma and lack of awareness.  • The significant role of #genetic and environmental factors in the #prevalence of Alzheimer's.  • The challenges in #healthcare access and representation in #clinicaltrials.  • #Groundbreaking #research in #Colombia and government initiatives like #Brazil's new national policy for Alzheimer's care. It's time to address these #challenges head-on and support efforts to #improve the lives of millions. #IGCPharma #WorldAlzheimersMonth #DementiaAwareness #AlzheimersResearch #LatinAmerica #HealthcareInnovation

IGC Pharma extends our deepest condolences to the family, friends, and colleagues of Dr. Lopera, coordinator of the #NeurosciencesGroup at the #UniversityofAntioquia (GNA - Grupo de Neurociencias de Antioquia) in Medellín, Colombia, and a #pioneer in Alzheimer's research for over 40 years. This year, Dr. Lopera was awarded the #Potamkin #Prize for his outstanding contributions to the field of early-onset #Alzheimer's #research. His unwavering dedication to Alzheimer's research and his compassionate work with families affected by the disease have left an indelible impact. He will be greatly missed by his family, colleagues, patients, and caregivers. Among his many accomplishments, we highlight his discovery of the presenilin 1 (PSEN1) #gene #mutation, known as 'the paisa mutation,' that causes early-onset familial Alzheimer's disease, as well as his discovery of a protective gene that may delay the onset of the disease. #AlzheimersResearch #DementiaScience #ScientificLegacy #ClinicalTrials #IGCPharma #FranciscoLopera #UniversityofAntioquia #AlzheimersDisease GNA - Grupo de Neurociencias de Antioquia